Logo image of SRRK

SCHOLAR ROCK HOLDING CORP (SRRK) Stock Fundamental Analysis

NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD

39.15  +1.14 (+3%)

After market: 39.15 0 (0%)

Fundamental Rating

2

SRRK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability. SRRK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SRRK has reported negative net income.
SRRK had a negative operating cash flow in the past year.
SRRK had negative earnings in each of the past 5 years.
In the past 5 years SRRK always reported negative operating cash flow.
SRRK Yearly Net Income VS EBIT VS OCF VS FCFSRRK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -89.85%, SRRK is doing worse than 71.76% of the companies in the same industry.
With a Return On Equity value of -152.56%, SRRK is not doing good in the industry: 65.01% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -89.85%
ROE -152.56%
ROIC N/A
ROA(3y)-44.72%
ROA(5y)-36.48%
ROE(3y)-67.3%
ROE(5y)-56.04%
ROIC(3y)N/A
ROIC(5y)N/A
SRRK Yearly ROA, ROE, ROICSRRK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

SRRK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRK Yearly Profit, Operating, Gross MarginsSRRK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

SRRK does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRRK has more shares outstanding than it did 1 year ago.
SRRK has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRRK has a worse debt to assets ratio.
SRRK Yearly Shares OutstandingSRRK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
SRRK Yearly Total Debt VS Total AssetsSRRK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 15.84 indicates that SRRK is not in any danger for bankruptcy at the moment.
SRRK has a better Altman-Z score (15.84) than 90.94% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that SRRK is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.37, SRRK is doing worse than 73.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 15.84
ROIC/WACCN/A
WACC9.58%
SRRK Yearly LT Debt VS Equity VS FCFSRRK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

SRRK has a Current Ratio of 6.04. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.04, SRRK is in the better half of the industry, outperforming 60.57% of the companies in the same industry.
SRRK has a Quick Ratio of 6.04. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.04, SRRK is doing good in the industry, outperforming 61.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 6.04
SRRK Yearly Current Assets VS Current LiabilitesSRRK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SRRK have decreased strongly by -20.51% in the last year.
SRRK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.53%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SRRK will show a very strong growth in Earnings Per Share. The EPS will grow by 25.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.51%
EPS Next 2Y-6.89%
EPS Next 3Y8.43%
EPS Next 5Y25.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRK Yearly Revenue VS EstimatesSRRK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SRRK Yearly EPS VS EstimatesSRRK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SRRK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRRK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRK Price Earnings VS Forward Price EarningsSRRK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRRK Per share dataSRRK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.89%
EPS Next 3Y8.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRRK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCHOLAR ROCK HOLDING CORP

NASDAQ:SRRK (2/20/2025, 5:20:00 PM)

After market: 39.15 0 (0%)

39.15

+1.14 (+3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners98.98%
Inst Owner Change17.94%
Ins Owners1.12%
Ins Owner Change-8.82%
Market Cap3.66B
Analysts85.33
Price Target46.63 (19.11%)
Short Float %17%
Short Ratio16.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.1%
Min EPS beat(2)-13.59%
Max EPS beat(2)3.39%
EPS beat(4)2
Avg EPS beat(4)-2.63%
Min EPS beat(4)-13.59%
Max EPS beat(4)3.39%
EPS beat(8)6
Avg EPS beat(8)8.24%
EPS beat(12)8
Avg EPS beat(12)10.38%
EPS beat(16)8
Avg EPS beat(16)3.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.6%
PT rev (3m)22.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 27.43
P/tB 27.43
EV/EBITDA N/A
EPS(TTM)-2.35
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0
BVpS1.43
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.85%
ROE -152.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.72%
ROA(5y)-36.48%
ROE(3y)-67.3%
ROE(5y)-56.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.85%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 6.04
Altman-Z 15.84
F-Score3
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)79.19%
Cap/Depr(5y)150.41%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.53%
EPS Next Y-24.51%
EPS Next 2Y-6.89%
EPS Next 3Y8.43%
EPS Next 5Y25.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.27%
EBIT Next 3Y22.9%
EBIT Next 5YN/A
FCF growth 1Y-13.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.7%
OCF growth 3YN/A
OCF growth 5YN/A